Julie Auger
|
| Title | Executive Director |
|---|
| School | UCSF Chancellor/EVC/FAS |
|---|
| Department | Executive Vice Chancellor |
|---|
| Address | 1855 Folsom Street, MCB San Francisco CA 94143
|
|---|
| Phone | 415-476-8065 |
|---|
|
|
Overview Julie came to UCSF in 2010 from the University of Chicago where she directed the operations of 30 unique core facilities as the Executive Director of Shared Research Operations for the Division of Biological Sciences and Associate Director of Core Facilities at the University’s Comprehensive Cancer Center. She helped lead the major overhaul in the organization and administration of shared research resources resulting in financial stabilization of cores, transparency in funding subsidies to facilities, improvement of under-performing operations by consolidation or service “sunsetting” and improved recruitment and retention of expert personnel. Julie developed her strong core facility management experience at the University of Illinois Urbana-Champaign and at the University of Chicago where she developed internationally reputed flow cytometry core facilities before applying her change management skills at the institutional level. “I am very excited by the opportunity to strengthen the research infrastructure at UCSF. Shared research facilities – cores – are one of the strongest underpinnings of discovery research today. I am passionate about ensuring effective, efficient access to expert personnel and state-of-the-art technologies and look forward to the challenges – physical and cultural – that UCSF presents within this regard,” Julie says. Julie grew up a "cheesehead" in Northern Wisconsin. In her spare time, she tries to keep tabs on her son Nikolas and partner Roger, both still in Chicago. She loves to travel, read and is an advocate of spontaneous happy hours.
Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
Researchers can login to make corrections and additions, or contact us for help.
-
Bour-Jordan H, Grogan JL, Tang Q, Auger JA, Locksley RM, Bluestone JA. CTLA-4 regulates the requirement for cytokine-induced signals in T(H)2 lineage commitment. Nat Immunol. 2003 Feb; 4(2):182-8.
-
Utset TO, Auger JA, Peace D, Zivin RA, Xu D, Jolliffe L, Alegre ML, Bluestone JA, Clark MR. Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. J Rheumatol. 2002 Sep; 29(9):1907-13.
-
Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluestone JA. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med. 2002 May 30; 346(22):1692-8.
-
Khattri R, Auger JA, Griffin MD, Sharpe AH, Bluestone JA. Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of Th2 responses. J Immunol. 1999 May 15; 162(10):5784-91.
-
Sperling AI, Auger JA, Ehst BD, Rulifson IC, Thompson CB, Bluestone JA. CD28/B7 interactions deliver a unique signal to naive T cells that regulates cell survival but not early proliferation. J Immunol. 1996 Nov 1; 157(9):3909-17.
-
Bashir A, Auger JA, Rayburn AL. Flow cytometric DNA analysis of wheat-rye addition lines. Cytometry. 1993 Nov; 14(8):843-7.
-
Rayburn AL, Auger JA, McMurphy LM. Estimating percentage constitutive heterochromatin by flow cytometry. Exp Cell Res. 1992 Jan; 198(1):175-8.
-
Xu C, Auger J. Chlorophyll a fluorescence measurements of isolated spinach thylakoids obtained by using single-laser-based flow cytometry. Cytometry. 1990; 11(3):349-58.
|
Julie's Networks
Click the "See All" links for more information and interactive visualizations!
Related Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Related Authors People who share similar concepts with this person. _
|